Tranexamic Acid in Lower Extremity Endoprosthetic Reconstruction for Oncologic Indications: A Retrospective Comparative Study of 617 Patients
Stephen W. Chenard, Akhil Rekulapelli, Riley S. Gilbertson, Connor S. Charton, William F. Hefley, Michael J. Colello, Jennifer L. Halpern, Herbert S. Schwartz, Daniel J. Johnson, Jonathan G. Schoenecker, Joshua M. Lawrenz · 2026
Read Tranexamic Acid in Lower Extremity Endoprosthetic Reconstruction for Oncologic Indications: A Retrospective Comparative Study of 617 Patients by Stephen W. Chenard, Akhil Rekulapelli, Riley S. Gilbertson, Connor S. Charton, William F. Hefley, Michael J. Colello, Jennifer L. Halpern, Herbert S. Schwartz, Daniel J. Johnson, Jonathan G. Schoenecker, Joshua M. Lawrenz (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13353127.txt.
Description
Background and ObjectivesWhile tranexamic acid (TXA) reduces blood loss in orthopedic surgery, thromboembolic concerns in cancer patients have limited adoption in orthopedic oncology. This study evaluated TXA efficacy and safety in patients undergoing endoprosthetic reconstruction for oncologic indications.MethodsThis retrospective single‐center study included 617 patients who underwent lower extremity endoprosthetic reconstruction for oncologic indications between 2000 and 2024.
Catalog record
| CREATOR | Stephen W. Chenard, Akhil Rekulapelli, Riley S. Gilbertson, Connor S. Charton, William F. Hefley, Michael J. Colello, Jennifer L. Halpern, Herbert S. Schwartz, Daniel J. Johnson, Jonathan G. Schoenecker, Joshua M. Lawrenz |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 35 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |